2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3648 Updated Results of a prospective multicenter Phase 2 study of response-adapted rituximab, chidamide, and Zanubrutinib±CHOP therapy in newly diagnosed double-expressor DLBCL

Zhiming Li, MD, Peng SUN, PhD2, Lu Zhang3, Xiangjun Fu4, Yirong Jiang, MD5, Zhi Guo, PhD6, Panpan LIU7, Yu Wang8, Hang Yang9, Kangming Huang10
1 Sun Yat-Sen University Cancer Center, Guangzhou, China
2 Sun Yat-Sen University Cancer Center, Guangzhou, China
3 Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, China
4 Hainan General Hospital, Haikou, China
5 Dongguan Hospital Affiliated to Southern Medical University, Dongguan, China
6 Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China
7 Sun Yat-Sen University Cancer Center, Guangzhou, China
8 Sun Yat-Sen University Cancer Center, Guangzhou, China
9 Sun Yat-Sen University Cancer Center, Guangzhou, China
10 Sun Yat-Sen University Cancer Center, Guangzhou, China

Background

Double-expressor lymphoma (DEL), characterized by concurrent MYC and BCL2 overexpression, represents a high-risk subtype of diffuse large B-cell lymphoma (DLBCL) with inferior outcomes following standard R-CHOP therapy. Incorporating targeted agents while reducing chemotherapy exposure remains an unmet clinical need for patients with DEL. In this prospective multicenter phase 2 study, response-adapted rituximab, chidamide, and zanubrutinib (RCZ) with or without CHOP therapy showed promising antitumor activity and acceptable toxicity in patients with newly diagnosed DEL in the initial analysis. Here, we present updated efficacy, safety, and biomarker analyses with extended follow-up.

Methods

This prospective, multicenter, open-label, single-arm phase 2 study (NCT05527912) enrolled patients with previously untreated DEL. Patients received RCZ, consisting of rituximab, chidamide, and zanubrutinib, in 21-day cycles. After two cycles of RCZ induction, treatment was adapted according to interim PET-CT response assessment. Patients achieving complete response (CR) continued RCZ consolidation without CHOP, whereas patients with partial response (PR) or stable disease (SD) received additional CHOP chemotherapy. The primary endpoint was end-of-treatment complete response rate (EOT-CRR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), safety, and exploratory circulating tumor DNA (ctDNA) analyses.

Results

From February 2023 to October 2024, 45 patients were enrolled, and 44 were evaluable for efficacy and safety analyses. The median age was 54 years (range, 22–67); 33 (75.0%) patients had non-GCB subtype, 20 (45.5%) had stage III–IV disease, and 16 (36.4%) had IPI scores ≥2. After two cycles of RCZ induction, interim PET-CT assessment showed CR in 19 patients (43.2%), PR in 19 patients (43.2%), SD in 3 patients (6.8%), and PD in 3 patients (6.8%). At end of treatment, the CR rate was 84.1% (37/44; 95% CI, 70.0–92.8%), and ORR was 88.6% (39/44; 95% CI, 76.0–95.4%). Response-adapted RCZ±CHOP therapy enabled chemotherapy omission in a substantial proportion of patients. Twenty-two patients (50.0%) completed treatment without CHOP exposure and received chemotherapy-free RCZ consolidation. Among this chemotherapy-sparing subgroup, the estimated 2-year PFS and OS rates were 78.9% and 94.7%, respectively. With a median follow-up of 22.4 months, median PFS and OS were not reached. The estimated 2-year PFS and OS rates in the overall cohort were 77.2% and 90.9%, respectively.
The most common treatment-emergent adverse events were hematologic, including neutropenia (79.5%), leukopenia (59.1%), thrombocytopenia (59.1%), and anemia (59.1%). No major adverse cardiovascular events or serious bleeding events were observed.
Exploratory biomarker analyses indicated that ctDNA status at Cycle 3 Day 1 was significantly associated with prognosis, with early ctDNA clearance correlating with favorable treatment outcomes.

Conclusions

Updated results from this prospective multicenter phase 2 study indicate that response-adapted RCZ±CHOP therapy achieved high response rates and durable disease control in previously untreated DEL while allowing chemotherapy omission in half of patients. These findings support RCZ-based response-adapted therapy as a promising chemotherapy-sparing approach for this high-risk molecularly defined DLBCL subgroup. A randomized phase 2 trial (NCT06890585) comparing zanubrutinib, chidamide, and rituximab induction with or without CHOP versus R-CHOP is ongoing to further prospectively evaluate this strategy.

Zhiming Li, MD: No relevant conflicts of interest to declare.